Skip to main content

Transforming the Treatment of Major Neuro­degene­rative Diseases of the Eye and Brain

Profile

Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharma executives and scientists, Galimedix’s novel small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry AMD, glaucoma and Alzheimer’s disease (AD), Galimedix’s initial areas of focus.

Our Aβ-targeting approach is strongly supported by our license deal with major ophthalmology player, Théa Open Innovation (TOI), as well as recent successes in the field of Alzheimer’s disease. The team’s extensive internal expertise in neurodegenerative diseases is complemented by a network of renowned international key opinion leaders.

Galimedix’s approach is to block a key step in the neurodegenerative process with a highly specific small molecule without impacting normal neuronal function. This important step – the formation of toxic oligomers and protofibrils of Aβ – has emerged as a central cause of neurodegeneration. This understanding is supported by recent approvals of Aβ-targeting therapies for AD, as well as numerous publications about the role of Aβ in dry AMD and glaucoma.

Our pipeline

Compelling pre-clinical data support the potential of Galimedix’s product candidates to slow or stop neurodegeneration and also restore lost neuronal function. With our lead program, topical GAL-101, supported by our partner, TOI, we are currently in a Phase 2 proof-of-concept study in dry AMD. The compound is Phase-2-ready in glaucoma, and clinical studies in AD and other indications are planned.

Current investors

Our efforts are supported by dedicated and highly specialized venture investors in vision science technology as well as a strategic partnership with major ophthalmology player, Théa Open Innovation (TOI).

SCIENTIFIC ADVISORY BOARD

Justis P. Ehlers, MD

COLE EYE INSTITUTE CLEVELAND CLINIC
CLEVELAND, OH, USA

Dun Jack Fu, MD

MOORFIELDS BIOMEDICAL RESEARCH CENTRE OPHTHALMOLOGY, UCL
LONDON, UK

Jeffrey S. Heier, MD

OPHTHALMIC CONSULTANTS OF BOSTON
BOSTON, MA, USA

Peter K. Kaiser, MD

COLE EYE INSTITUTE CLEVELAND CLINIC
CLEVELAND, OH, USA

Eleonora G. Lad, MD, PhD

DUKE UNIVERSITY MEDICAL CENTER
DURHAM, NC, USA

Ursula Schmidt-Erfurth, MD

MEDICAL UNIVERSITY OF VIENNA
VIENNA, AUSTRIA

Omer Trivizki, MD, MBA

TEL-AVIV MEDICAL CENTER
TEL-AVIV, ISRAEL

 

 

Dale Usner, PhD

OPHTHALSTAT
MESA, AZ, USA

Meet the team behind our
pioneering science

take me back

title

meta

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.